KẾT QUẢ ĐIỀU TRỊ UNG THƯ ĐẠI TRỰC TRÀNG DI CĂN BẰNG PHÁC ĐỒ MFOLFOX6 KẾT HỢP BEVACIZUMAB TẠI BỆNH VIỆN HỮU NGHỊ VIỆT ĐỨC

Abstract

Objectives: This study aimed to evaluate the efficacy and safety of the mFOLFOX6 regimen combined with Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) at Viet Duc University Hospital. Materials and methods: This was a retrospective descriptive studywith longitudinal follow-up. A total of 53 patients diagnosed with metastatic colorectal cancer were treated with mFOLFOX6 plus Bevacizumab from January 2019 to January 2025 at Viet Duc University Hospital. Results: Patient characteristics: The median age was 55.6 years. The male-to-female ratio was 1.1. The sigmoid colon was the most common tumor location (28.3%). Moderately differentiated adenocarcinoma was the most frequent histological type (59.5%). At the time of first diagnosis, 92.5% of cases were already at the metastatic disease. Results of treatment: The objective response rate (ORR) was 63.3%, and the disease control rate (DCR) was 81.6%. The median progression-free survival (PFS) was 12 months (range: 4 to 43 months). Common adverse events included neutropenia, thrombocytopenia, diarrhea, peripheral sensory neuropathy, nausea and vomiting (mostly grade 1 or 2) with minimal impact on treatment continuity. Bevacizumab-related toxicity were primarily mild hypertension, which was manageable. Conclusions: The combination of mFOLFOX6 and Bevacizumab was an effective and safe regimen for patients with metastatic colorectal cancer, contributing to improved survival outcomes. The toxicity profile was acceptable and manageable.